<< Study: Physicians attribute 26% of overall healthcare costs to the practice of defensive medicine | Pelosi releases statement on HHS Secretary's decision to increase aid to states for Medicare Part D payment >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Nederlands | हिन्दी | Русский

Cappella promotes serial IVUS analysis & Sideguard 3.25 device at Rome JIM

Published on February 20, 2010 at 3:05 AM · No Comments

Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading